These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 20228155)

  • 21. Selective diapedesis of Th1 cells induced by endothelial cell RANTES.
    Kawai T; Seki M; Hiromatsu K; Eastcott JW; Watts GF; Sugai M; Smith DJ; Porcelli SA; Taubman MA
    J Immunol; 1999 Sep; 163(6):3269-78. PubMed ID: 10477596
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thrombin-induced phosphorylation of the regulatory light chain of myosin II in cultured bovine corneal endothelial cells.
    Satpathy M; Gallagher P; Lizotte-Waniewski M; Srinivas SP
    Exp Eye Res; 2004 Oct; 79(4):477-86. PubMed ID: 15381032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CML-1 inhibits TNF-alpha-induced NF-kappaB activation and adhesion molecule expression in endothelial cells through inhibition of IkBalpha kinase.
    Mo SJ; Son EW; Lee SR; Lee SM; Shin DH; Pyo S
    J Ethnopharmacol; 2007 Jan; 109(1):78-86. PubMed ID: 16920299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High glucose-induced upregulation of Rho/Rho-kinase via platelet-derived growth factor receptor-beta increases migration of aortic smooth muscle cells.
    Akiyama N; Naruse K; Kobayashi Y; Nakamura N; Hamada Y; Nakashima E; Matsubara T; Oiso Y; Nakamura J
    J Mol Cell Cardiol; 2008 Aug; 45(2):326-32. PubMed ID: 18561944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways.
    Penna G; Fibbi B; Amuchastegui S; Corsiero E; Laverny G; Silvestrini E; Chavalmane A; Morelli A; Sarchielli E; Vannelli GB; Gacci M; Colli E; Maggi M; Adorini L
    Prostate; 2009 Apr; 69(5):480-93. PubMed ID: 19107880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease.
    Peng F; Wu D; Gao B; Ingram AJ; Zhang B; Chorneyko K; McKenzie R; Krepinsky JC
    Diabetes; 2008 Jun; 57(6):1683-92. PubMed ID: 18356410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-inflammatory compounds of plant origin. Part II. modulation of pro-inflammatory cytokines, chemokines and adhesion molecules.
    Calixto JB; Campos MM; Otuki MF; Santos AR
    Planta Med; 2004 Feb; 70(2):93-103. PubMed ID: 14994184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation.
    Mourey RJ; Burnette BL; Brustkern SJ; Daniels JS; Hirsch JL; Hood WF; Meyers MJ; Mnich SJ; Pierce BS; Saabye MJ; Schindler JF; South SA; Webb EG; Zhang J; Anderson DR
    J Pharmacol Exp Ther; 2010 Jun; 333(3):797-807. PubMed ID: 20237073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 7-Chloro-6-piperidin-1-yl-quinoline-5,8-dione (PT-262), a novel ROCK inhibitor blocks cytoskeleton function and cell migration.
    Tsai CC; Liu HF; Hsu KC; Yang JM; Chen C; Liu KK; Hsu TS; Chao JI
    Biochem Pharmacol; 2011 Apr; 81(7):856-65. PubMed ID: 21276421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological characterization of SAR407899, a novel rho-kinase inhibitor.
    Löhn M; Plettenburg O; Ivashchenko Y; Kannt A; Hofmeister A; Kadereit D; Schaefer M; Linz W; Kohlmann M; Herbert JM; Janiak P; O'Connor SE; Ruetten H
    Hypertension; 2009 Sep; 54(3):676-83. PubMed ID: 19597037
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Linking phenotype to kinase: identification of a novel benzoxaborole hinge-binding motif for kinase inhibition and development of high-potency rho kinase inhibitors.
    Akama T; Dong C; Virtucio C; Sullivan D; Zhou Y; Zhang YK; Rock F; Freund Y; Liu L; Bu W; Wu A; Fan XQ; Jarnagin K
    J Pharmacol Exp Ther; 2013 Dec; 347(3):615-25. PubMed ID: 24049062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in the studies of roles of Rho/Rho-kinase in diseases and the development of its inhibitors.
    Guan R; Xu X; Chen M; Hu H; Ge H; Wen S; Zhou S; Pi R
    Eur J Med Chem; 2013; 70():613-22. PubMed ID: 24211637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ROCK2 Regulates Monocyte Migration and Cell to Cell Adhesion in Vascular Endothelial Cells.
    Takeda Y; Matoba K; Kawanami D; Nagai Y; Akamine T; Ishizawa S; Kanazawa Y; Yokota T; Utsunomiya K
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30884801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The role of Rho-kinase pathway on PAH].
    Fukumoto Y; Shimokawa H
    Nihon Rinsho; 2008 Nov; 66(11):2091-6. PubMed ID: 19051725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors.
    Yin Y; Lin L; Ruiz C; Khan S; Cameron MD; Grant W; Pocas J; Eid N; Park H; Schröter T; Lograsso PV; Feng Y
    J Med Chem; 2013 May; 56(9):3568-81. PubMed ID: 23570561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 2, optimization for blood pressure reduction in spontaneously hypertensive rats.
    Ginn JD; Bosanac T; Chen R; Cywin C; Hickey E; Kashem M; Kerr S; Kugler S; Li X; Prokopowicz A; Schlyer S; Smith JD; Turner MR; Wu F; Young ER
    Bioorg Med Chem Lett; 2010 Sep; 20(17):5153-6. PubMed ID: 20678931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel ROCK inhibitors for the treatment of pulmonary arterial hypertension.
    Shaw D; Hollingworth G; Soldermann N; Sprague E; Schuler W; Vangrevelinghe E; Duggan N; Thomas M; Kosaka T; Waters N; van Eis MJ
    Bioorg Med Chem Lett; 2014 Oct; 24(20):4812-7. PubMed ID: 25248678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of Rho kinases increases directional motility of microvascular endothelial cells.
    Breyer J; Samarin J; Rehm M; Lautscham L; Fabry B; Goppelt-Struebe M
    Biochem Pharmacol; 2012 Mar; 83(5):616-26. PubMed ID: 22192821
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benzothiophene containing Rho kinase inhibitors: Efficacy in an animal model of glaucoma.
    Davis RL; Kahraman M; Prins TJ; Beaver Y; Cook TG; Cramp J; Cayanan CS; Gardiner EM; McLaughlin MA; Clark AF; Hellberg MR; Shiau AK; Noble SA; Borchardt AJ
    Bioorg Med Chem Lett; 2010 Jun; 20(11):3361-6. PubMed ID: 20434334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The development of benzimidazoles as selective rho kinase inhibitors.
    Sessions EH; Smolinski M; Wang B; Frackowiak B; Chowdhury S; Yin Y; Chen YT; Ruiz C; Lin L; Pocas J; Schröter T; Cameron MD; LoGrasso P; Feng Y; Bannister TD
    Bioorg Med Chem Lett; 2010 Mar; 20(6):1939-43. PubMed ID: 20167489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.